Merck KGaA, National MS Society distribute $1.3 million for early-stage drug research
NEW YORK — Three organizations will receive part of $1.3 million in funding that German drug maker Merck KGaA and the National Multiple Sclerosis Society are distributing for MS research.
EMD Serono, the name the Merck KGaA uses in the United States to avoid confusion with U.S.-based Merck & Co., and the National MS Society said the money will help encourage early-stage drug discovery for the autoimmune disease.
The recipients of the funding are the University of California San Diego School of Medicine, which is receiving $285,000 over 18 months; the Emory University School of Medicine, receiving $471,333 over 21 months; and Euroscreen SA, receiving $501,657 over 12 months.
Amneal launches new GERD treatment
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.
Amneal announced Tuesday the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength, which it is marketing in the United States under a contract with Hanmi Pharmaceutical Co. The drug is expected to begin shipping Wednesday in 30-count bottles.
The drug is being marketed as an alternative to AstraZeneca’s Nexium (esomeprazole magnesium), though it received approval from the Food and Drug Administration in August as a branded drug. The drug contains a similar active ingredient to Nexium, but in a different salt form.
Study sees shift from pharmaceuticals to biologics for generic drug makers through 2020
BURLINGTON, Mass. — Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.
The report, "Indian Generics Manufacturers Penetrate U.S. Generics Market: Case Studies in Success and Failure and Near-Term Opportunities," released Tuesday by healthcare market research firm Decision Resources, found that during that time, the loss of brand sales to generics will be more than $155 billion, with 2015 being the biggest single year for patent expiries. Through 2020, the opportunities for generic drug makers will shift increasingly from small-molecule drugs to biologics.
"Teva is the leading global generics company and provides Indian companies with a template for successful growth," Decision Resources group SVP Kate Hohenberg said. "The company’s growth has been achieved largely through acquisitions to expand its global footprint and technological capabilities."
Currently, Teva, Mylan and Actavis lead the U.S. generics industry, while Indian companies have increased their presence here, including Ranbaxy Labs, Dr. Reddy’s Labs and Lupin. However, they face such challenges as the requirement for increased spending on research and development and investment in advanced manufacturing technologies, as opportunities shift from generic pharmaceuticals to biosimilars.